JCR Pharmaceuticals Co., Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2024. For the full year, the company expected net sales of JPY 45,400 million, operating income of JPY 10,500 million, profit attributable to owners of parent of JPY 7,300 million and basic earnings per share of JPY 58.71 against previous forecast of net sales of JPY 36,900 million, operating profit of JPY 5,600 million, profit attributable to owners of parent of JPY 3,800 million and basic earnings per share of JPY 30.56.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
806 JPY | -0.86% | +1.13% | -31.23% |
Apr. 25 | JCR Pharmaceuticals Co., Ltd. Announces Management Changes, Effective as of June 26, 2024 | CI |
Mar. 21 | US Fed Rate Outlook Catapults Japanese Shares to Fresh 52-Week Peak | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.23% | 658M | |
+31.52% | 662B | |
+21.96% | 546B | |
-5.21% | 359B | |
+17.02% | 323B | |
+5.01% | 289B | |
+13.68% | 234B | |
+3.81% | 198B | |
-10.63% | 194B | |
+3.98% | 167B |
- Stock Market
- Equities
- 4552 Stock
- News JCR Pharmaceuticals Co., Ltd.
- JCR Pharmaceuticals Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024